Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia

British Journal of Haematology

Volumn 153, Issue 2, 2011, Pages 149-167

  Bacher, Ulrike ^a   Haferlach, Torsten ^b   Schnittger, Susanne ^b   Kreipe, Hans ^c   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Allogeneic haematopoietic stem cell transplantation; Chronic myelomonocytic leukaemia; Demethylating agents; Molecular mutations

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 9 NITRO CAMPTOTHECIN; ALEMTUZUMAB; AMSACRINE; AZACITIDINE; BUSULFAN; CALCITRIOL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; FLUDARABINE; HYDROXYUREA; ISOTRETINOIN; LONAFARNIB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID; THIOTEPA; TOPOTECAN; TREOSULFAN; UNCLASSIFIED DRUG; VALPROIC ACID;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CBL GENE; CHROMOSOME ANALYSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; CYTOPENIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENE MUTATION; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; IDH GENE; IMMUNOHISTOCHEMISTRY; INFECTION; INJECTION SITE IRRITATION; JAK2 GENE; LEUKEMIA REMISSION; LOW DRUG DOSE; MOLECULAR GENETICS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; ONCOGENE RAS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RUNX1 GENE; SEPSIS; TET2 GENE; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE;

FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MUTATION; NEOPLASM PROTEINS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79953074952     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08631.x     Document Type: Review

References (90)

1. Arber, D.A., Brunning, R.D., Le Beau, M.M., Falini, B., Vardiman, J.W., Porwit, A., Thiele, J. & Bloomfield, C.D. (2008) Acute myeloid leukemia with recurrent genetic abnormalities. In: WHO Classification of Haematopoietic and Lymphoid Tissues (ed. by S.H. Swerdlow, E. Campo, N. Lee Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman), pp. 110-123. IARC Press, Lyon.
2. Aribi, A., Borthakur, G., Ravandi, F., Shan, J., Davisson, J., Cortes, J. & Kantarjian, H. (2007) Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukaemia. Cancer, 109, 713-717.
3. Bacher, U., Haferlach, T., Kern, W., Hiddemann, W., Schnittger, S. & Schoch, C. (2005) Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Annals of Hematology, 84, 250-257.
4. Bacher, U., Haferlach, T., Kern, W., Haferlach, C. & Schnittger, S. (2007) A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukaemia. Haematologica, 92, 744-752.
5. Bain, B.J., Gilliland, G., Horny, H.-P. & Vardiman, J.W. (2008) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. In: WHO Classification of Haematopoietic and Lymphoid Tissues (ed. by S.H. Swerdlow, E. Campo, N. Lee Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman), pp. 68-73. IARC Press, Lyon.
6. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
7. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H., Sultan, C. & Cox, C. (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British co-operative leukaemia group. British Journal of Haematology, 87, 746-754.
8. Beran, M., Estey, E., O'Brien, S., Cortes, J., Koller, C.A., Giles, F.J., Kornblau, S., Andreeff, M., Vey, N., Pierce, S.R., Hayes, K., Wong, G.C., Keating, M. & Kantarjian, H. (1999) Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Journal of Clinical Oncology, 17, 2819-2830.
9. Bowen, D.T. (2005) Chronic myelomonocytic leukaemia: lost in classification? Hematology & Oncology, 23, 26-33.
10. Breccia, M., Latagliata, R., Mengarelli, A., Biondo, F., Mandelli, F. & Alimena, G. (2004) Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukaemia: a retrospective analysis of 83 patients from a single institution. Haematologica, 89, 866-868.
11. Büsche, G., Hehlmann, R., Hecker, H., Heimpel, H., Heinze, B., Schmeil, A., Pfirrmann, M., Gomez, G., Tobler, A., Herrmann, H., Kappler, M., Hasford, J., Buhr, T., Kreipe, H.H. & Georgii, A. (2003) Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. Leukemia, 17, 2444-2453.
12. Caligiuri, M.A., Briesewitz, R., Yu, J., Wang, L., Wei, M., Arnoczky, K.J., Marburger, T.B., Wen, J., Perrotti, D., Bloomfield, C.D. & Whitman, S.P. (2007) Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukaemia. Blood, 110, 1022-1024.
13. Carbuccia, N., Murati, A., Trouplin, V., Brecqueville, M., Adelaide, J., Rey, J., Vainchenker, W., Bernard, O.A., Chaffanet, M., Vey, N., Birnbaum, D. & Mozziconacci, M.J. (2009) Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukaemia, 23, 2183-2186.
14. Caudill, J.S., Sternberg, A.J., Li, C.Y., Tefferi, A., Lasho, T.L. & Steensma, D.P. (2006) C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. British Journal of Haematology, 133, 638-641.
15. Chen, B., Zhao, W.L., Jin, J., Xue, Y.Q., Cheng, X., Chen, X.T., Cui, J., Chen, Z.M., Cao, Q., Yang, G., Yao, Y., Xia, H.L., Tong, J.H., Li, J.M., Chen, J., Xiong, S.M., Shen, Z.X., Waxman, S., Chen, Z. & Chen, S.J. (2005) Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukaemia, 19, 767-775.
16. Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., Löwenberg, B., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., Gore, S. & Greenberg, P.L.; World Health Organization (WHO) international working group. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 96, 3671-3674.
17. Costa, R.B. (2010) Activity of azacitidine in chronic myelomonocytic leukaemia. 2010 ASCO annual meeting. Journal of Clinical Oncology, 28, 15s, Abstract 6574.
18. Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Masse, A., Kosmider, O., Le Couedic, J.P., Robert, F., Alberdi, A., Lecluse, Y., Plo, I., Dreyfus, F.J., Marzac, C., Casadevall, N., Lacombe, C., Romana, S.P., Dessen, P., Soulier, J., Viguie, F., Fontenay, M., Vainchenker, W. & Bernard, O.A. (2009) Mutation in TET2 in myeloid cancers. New England Journal of Medicine, 360, 2289-2301.
19. Depil, S., Deconinck, E., Milpied, N., Sutton, L., Witz, F., Jouet, J.P., Damaj, G. & Yakoub-Agha, I. (2004) Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplantation, 33, 531-534.
20. Droin, N., Jacquel, A., Hendra, J.B., Racoeur, C., Truntzer, C., Pecqueur, D., Benikhlef, N., Ciudad, M., Guery, L., Jooste, V., Dufour, E., Fenaux, P., Quesnel, B., Kosmider, O., Fontenay, M., Ducoroy, P. & Solary, E. (2010) Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukaemia. Blood, 115, 78-88.
21. Dunbar, A.J., Gondek, L.P., O'Keefe, C.L., Makishima, H., Rataul, M.S., Szpurka, H., Sekeres, M.A., Wang, X.F., McDevitt, M.A. & Maciejewski, J.P. (2008) 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Research, 68, 10349-10357.
22. Edlin, R., Connock, M., Tubeuf, S., Round, J., Fry-Smith, A., Hyde, C. & Greenheld, W. (2010) Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Health Technology Assessment, 14(Suppl. 1), 69-74.
23. Elliott, M.A. (2006) Chronic neutrophilic leukaemia and chronic myelomonocytic leukaemia: WHO defined. Best Practice & Research. Clinical haematology, 19, 571-593.
24. Elliott, M.A., Tefferi, A., Hogan, W.J., Letendre, L., Gastineau, D.A., Ansell, S.M., Dispenzieri, A., Gertz, M.A., Hayman, S.R., Inwards, D.J., Lacy, M.Q., Micallef, I.N., Porrata, L.F. & Litzow, M.R. (2006) Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukaemia. Bone Marrow Transplantation, 37, 1003-1008.
25. Feldman, E.J., Cortes, J., DeAngelo, D.J., Holyoake, T., Simonsson, B., O'Brien, S.G., Reiffers, J., Turner, A.R., Roboz, G.J., Lipton, J.H., Maloisel, F., Colombat, P., Martinelli, G., Nielsen, J.L., Petersdorf, S., Guilhot, F., Barker, J., Kirschmeier, P., Frank, E., Statkevich, P., Zhu, Y., Loechner, S. & List, A. (2008) On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukaemia. Leukaemia, 22, 1707-1711.
26. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C. & Silverman, L.R. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The Lancet Oncology, 10, 223-232.
27. Fisher, C.L., Pineault, N., Brookes, C., Helgason, C.D., Ohta, H., Bodner, C., Hess, J.L., Humphries, R.K. & Brock, H.W. (2010) Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukaemia. Blood, 115, 38-46.
28. Gelsi-Boyer, V., Trouplin, V., Adelaide, J., Aceto, N., Remy, V., Pinson, S., Houdayer, C., Arnoulet, C., Sainty, D., Bentires-Alj, M., Olschwang, S., Vey, N., Mozziconacci, M.J., Birnbaum, D. & Chaffanet, M. (2008) Genome profiling of chronic myelomonocytic leukaemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer, 8, 299.
29. Gelsi-Boyer, V., Trouplin, V., Adelaide, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., Olschwang, S., Xerri, L., Chaffanet, M., Mozziconacci, M.J., Vey, N. & Birnbaum, D. (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 145, 788-800.
30. Gerhartz, H.H., Marcus, R., Delmer, A., Zwierzina, H., Suciu, S., Dardenne, M., Solbu, G., de Witte, T., Jacobs, A., Visani, G., Fiere, D., Sonneveld, P., Labar, B., Hoffbrand, A.V., Fenaux, P., Hayat, M., Thyss, A., Debusscher, L., Coiffier, B., Sizoo, W., Willemze, R., Ribeiro, M., Mandelli, F., Burghouts, G., Cauchie, C., Peetermans, M., Roozendal, K.J., Goudsmit, R., Douer, D., Castoldi, G.L., Stern, A. & Zittoun, R. (1994) A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukaemia. EORTC leukaemia co-operative group. Leukaemia, 8, 16-23.
31. Germing, U., Gattermann, N., Minning, H., Heyll, A. & Aul, C. (1998) Problems in the classification of CMML - dysplastic versus proliferative type. Leukemia Research, 22, 871-878.
32. Germing, U., Strupp, C., Aivado, M. & Gattermann, N. (2002) New prognostic parameters for chronic myelomonocytic leukaemia. Blood, 100, 731-732.
33. Germing, U., Kundgen, A. & Gattermann, N. (2004) Risk assessment in chronic myelomonocytic leukaemia (CMML). Leukemia & Lymphoma, 45, 1311-1318.
34. Gorczyca, W. (2004) Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukaemia (AML-M5), acute myelomonocytic leukaemia (AML-M4), and chronic myelomonocytic leukaemia (CMML). Methods in Cell Biology, 75, 665-677.
35. Grand, F.H., Hidalgo-Curtis, C.E., Ernst, T., Zoi, K., Zoi, C., McGuire, C., Kreil, S., Jones, A., Score, J., Metzgeroth, G., Oscier, D., Hall, A., Brandts, C., Serve, H., Reiter, A., Chase, A.J. & Cross, N.C. (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood, 113, 6182-6192.
36. Green, A. & Beer, P. (2010) Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. New England Journal of Medicine, 362, 369-370.
37. Gunby, R.H., Cazzaniga, G., Tassi, E., Le Coutre, P., Pogliani, E., Specchia, G., Biondi, A. & Gambacorti-Passerini, C. (2003) Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukaemia. Haematologica, 88, 408-415.
38. Haase, D., Germing, U., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kundgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A.A., Aul, C., Trümper, L., Krieger, O., Stauder, R., Müller, T.H., Wimazal, F., Valent, P., Fonatsch, C. & Steidl, C. (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood, 110, 4385-4395.
39. Jankowska, A.M., Szpurka, H., Tiu, R.V., Makishima, H., Afable, M., Huh, J., O'Keefe, C.L., Ganetzky, R., McDevitt, M.A. & Maciejewski, J.P. (2009) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood, 113, 6403-6410.
40. Jurado, M., Deeg, H.J., Storer, B., Anasetti, C., Anderson, J.E., Bryant, E., Chauncey, T., Doney, K., Flowers, M.E., Hansen, J., Martin, P.J., Nash, R.A., Petersdorf, E., Radich, J., Sale, G., Sandmaier, B.M., Storb, R., Wade, J., Witherspoon, R. & Appelbaum, F.R. (2002) Haematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable non-relapse mortality. Biology of Blood and Marrow Transplantation, 8, 161-169.
41. Kantarjian, H., Issa, J.P., Rosenfeld, C.S., Bennett, J.M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., Helmer, R., III, Shen, L., Nimer, S.D., Leavitt, R., Raza, A. & Saba, H. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 106, 1794-1803.
42. Kerbauy, D.M., Chyou, F., Gooley, T., Sorror, M.L., Scott, B., Pagel, J.M., Myerson, D., Appelbaum, F.R., Storb, R. & Deeg, H.J. (2005) Biology of blood and marrow transplantation. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biology of Blood and Marrow Transplantation, 11, 713-720.
43. Ko, M., Huang, Y., Jankowska, A.M., Pape, U.J., Tahiliani, M., Bandukwala, H.S., An, J., Lamperti, E.D., Koh, K.P., Ganetzky, R., Liu, X.S., Aravind, L., Agarwal, S., Maciejewski, J.P. & Rao, A. (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature, 468, 839-843.
44. Kohlmann, A., Grossmann, V., Klein, H.U., Schindela, S., Weiss, T., Kazak, B., Dicker, F., Schnittger, S., Dugas, M., Kern, W., Haferlach, C. & Haferlach, T. (2010) Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukaemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. Journal of Clinical Oncology, 28, 3858-3865.
45. Kosmider, O., Gelsi-Boyer, V., Ciudad, M., Racoeur, C., Jooste, V., Vey, N., Quesnel, B., Fenaux, P., Bastie, J.N., Beyne-Rauzy, O., Stamatoulas, A., Dreyfus, F., Ifrah, N., de Botton, S., Vainchenker, W., Bernard, O.A., Birnbaum, D., Fontenay, M. & Solary, E. (2009a) TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukaemia. Haematologica, 94, 1676-1681.
46. Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguie, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., Vey, N., Hunault-Berger, M., Fenaux, P., Mansat-De Mas, V., Delabesse, E., Guardiola, P., Lacombe, C., Vainchenker, W., Preudhomme, C., Dreyfus, F., Bernard, O.A., Birnbaum, D. & Fontenay, M. (2009b) TET2 mutation is an independent favourable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 114, 3285-3291.
47. Kosmider, O., Gelsi-Boyer, V., Slama, L., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Hunault-Berger, M., Slama, B., Vey, N., Lacombe, C., Solary, E., Birnbaum, D., Bernard, O.A. & Fontenay, M. (2010) Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukaemia, 24, 1094-1096.
48. Krishnamurthy, P., Lim, Z.Y., Nagi, W., Kenyon, M., Mijovic, A., Ireland, R., Marsh, J., Ho, A.Y., Mufti, G.J. & Pagliuca, A. (2010) Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant., 45, 1502-1507.
49. Kröger, N., Zabelina, T., Guardiola, P., Runde, V., Sierra, J., Van Biezen, A., Niederwieser, D., Zander, A.R. & De Witte, T. (2002) Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic leukaemia working party of the European group for blood and marrow transplantation (EBMT). British Journal of Haematology, 118, 67-73.
50. Kuendgen, A., Strupp, C., Aivado, M., Bernhardt, A., Hildebrandt, B., Haas, R., Germing, U. & Gattermann, N. (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood, 104, 1266-1269.
51. Kuo, M.C., Liang, D.C., Huang, C.F., Shih, Y.S., Wu, J.H., Lin, T.L. & Shih, L.Y. (2009) RUNX1 mutations are frequent in chronic myelomonocytic leukaemia and mutations at the C-terminal region might predict acute myeloid leukaemia transformation. Leukemia, 23, 1426-1431.
52. Langemeijer, S.M., Kuiper, R.P., Berends, M., Knops, R., Aslanyan, M.G., Massop, M., Stevens-Linders, E., van Hogen, P., van Kessel, A.G., Raymakers, R.A., Kamping, E.J., Verhoef, G.E., Verburgh, E., Hagemeijer, A., Vandenberghe, P., De Witte, T., van der Reijden, B.A. & Jansen, J.H. (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genetics, 41, 838-842.
53. Laport, G.G., Sandmaier, B.M., Storer, B.E., Scott, B.L., Stuart, M.J., Lange, T., Maris, M.B., Agura, E.D., Chauncey, T.R., Wong, R.M., Forman, S.J., Petersen, F.B., Wade, J.C., Epner, E., Bruno, B., Bethge, W.A., Curtin, P.T., Maloney, D.G., Blume, K.G. & Storb, R.F. (2008) Reduced-intensity conditioning followed by allogeneic haematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biology of Blood and Marrow Transplantation, 14, 246-255.
54. Levine, R.L., Loriaux, M., Huntly, B.J., Loh, M.L., Beran, M., Stoffregen, E., Berger, R., Clark, J.J., Willis, S.G., Nguyen, K.T., Flores, N.J., Estey, E., Gattermann, N., Armstrong, S., Look, A.T., Griffin, J.D., Bernard, O.A., Heinrich, M.C., Gilliland, D.G., Druker, B. & Deininger, M.W. (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukaemia and acute myeloid leukaemia, but not in acute lymphoblastic leukaemia or chronic lymphocytic leukaemia. Blood, 106, 3377-3379.
55. Loh, M.L., Martinelli, S., Cordeddu, V., Reynolds, M.G., Vattikuti, S., Lee, C.M., Wulfert, M., Germing, U., Haas, P., Niemeyer, C., Beran, M.E., Strom, S., Lübbert, M., Sorcini, M., Estey, E.H., Gattermann, N. & Tartaglia, M. (2005) Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia. Leukemia Research, 29, 459-462.
56. Magnusson, M.K., Meade, K.E., Nakamura, R., Barrett, J. & Dunbar, C.E. (2002) Activity of STI571 in chronic myelomonocytic leukaemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood, 100, 1088-1091.
57. Makishima, H., Cazzolli, H., Szpurka, H., Dunbar, A., Tiu, R., Huh, J., Muramatsu, H., O'Keefe, C., Hsi, E., Paquette, R.L., Kojima, S., List, A.F., Sekeres, M.A., McDevitt, M.A. & Maciejewski, J.P. (2009) Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. Journal of Clinical Oncology, 27, 6109-6116.
58. Marcondes, A.M., Mhyre, A.J., Stirewalt, D.L., Kim, S.H., Dinarello, C.A. & Deeg, H.J. (2008) Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukaemia modulates apoptosis and impairs NK function. Proceedings of the National Academy of Sciences of the United States of America, 105, 2865-2870.
59. Maschek, H., Georgii, A., Kaloutsi, V., Werner, M., Bandecar, K., Kressel, M.G., Choritz, H., Freund, M. & Hufnagl, D. (1992) Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. European Journal of Haematology, 48, 208-214.
60. Mittal, P., Saliba, R.M., Giralt, S.A., Shahjahan, M., Cohen, A.I., Karandish, S., Onida, F., Beran, M., Champlin, R.E. & de Lima, M. (2004) Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukaemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukaemia. Bone Marrow Transplantation, 33, 1005-1009.
61. Ngo, N.T., Lampert, I.A. & Naresh, K.N. (2008) Bone marrow trephine morphology and immunohistochemical findings in chronic myelomonocytic leukaemia. British Journal of Haematology, 141, 771-781.
62. Ocheni, S., Kröger, N., Zabelina, T., Zander, A.R. & Bacher, U. (2009) Outcome of allo-SCT for chronic myelomonocytic leukaemia. Bone Marrow Transplantation, 43, 659-661.
63. Oki, Y., Jelinek, J., Shen, L., Kantarjian, H.M. & Issa, J.P. (2008) Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukaemia. Blood, 111, 2382-2384.
64. Onida, F., Kantarjian, H.M., Smith, T.L., Ball, G., Keating, M.J., Estey, E.H., Glassman, A.B., Albitar, M., Kwari, M.I. & Beran, M. (2002) Prognostic factors and scoring systems in chronic myelomonocytic leukaemia: a retrospective analysis of 213 patients. Blood, 99, 840-849.
65. Orazi, A., Bennett, J., Germing, U., Brunning, R., Bain, B. & Thiele, J. (2008) Chronic myelomonocytic leukaemia. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed. by S. Swerdlow, E. Campo, N. Lee Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J. Vardiman), pp. 76-79. IARC Press, Lyon.
66. Pich, A., Riera, L., Sismondi, F., Godio, L., Davico, B.L., Marmont, F. & Francia di Celle, P. (2009) JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. Journal of Clinical Pathology, 62, 798-801.
67. Qubaja, M., Marmey, B., Le Tourneau, A., Haiat, S., Cazals-Hatem, D., Fabiani, B., Diebold, J., Marie, J.P., Audouin, J., Geissmann, F. & Molina, T.J. (2009) The detection of CD14 and CD16 in paraffin-embedded bone marrow biopsies is useful for the diagnosis of chronic myelomonocytic leukaemia. Virchows Archiv, 454, 411-419.
68. Quintas-Cardama, A., Kantarjian, H., O'Brien, S., Jabbour, E., Giles, F., Ravandi, F., Faderl, S., Pierce, S., Shan, J., Verstovsek, S. & Cortes, J. (2006) Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukaemia. Cancer, 107, 1525-1529.
69. Reindl, C., Quentmeier, H., Petropoulos, K., Greif, P.A., Benthaus, T., Argiropoulos, B., Mellert, G., Vempati, S., Duyster, J., Buske, C., Bohlander, S.K., Humphries, K.R., Hiddemann, W. & Spiekermann, K. (2009) CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukaemia/myelodysplastic syndrome subtypes. Clinical Cancer Research, 15, 2238-2247.
70. Ricci, C., Fermo, E., Corti, S., Molteni, M., Faricciotti, A., Cortelezzi, A., Lambertenghi, D.G., Beran, M. & Onida, F. (2010) RAS mutations contribute to evolution of chronic myelomonocytic leukaemia to the proliferative variant. Clinical Cancer Research, 16, 2246-2256.
71. Sanada, M., Suzuki, T., Shih, L.Y., Otsu, M., Kato, M., Yamazaki, S., Tamura, A., Honda, H., Sakata-Yanagimoto, M., Kumano, K., Oda, H., Yamagata, T., Takita, J., Gotoh, N., Nakazaki, K., Kawamata, N., Onodera, M., Nobuyoshi, M., Hayashi, Y., Harada, H., Kurokawa, M., Chiba, S., Mori, H., Ozawa, K., Omine, M., Hirai, H., Nakauchi, H., Koeffler, H.P. & Ogawa, S. (2009) Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature, 460, 904-908.
72. Sargin, B., Choudhary, C., Crosetto, N., Schmidt, M.H., Grundler, R., Rensinghoff, M., Thiessen, C., Tickenbrock, L., Schwable, J., Brandts, C., August, B., Koschmieder, S., Bandi, S.R., Duyster, J., Berdel, W.E., Müller-Tidow, C., Dikic, I. & Serve, H. (2007) Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood, 110, 1004-1012.
73. Schmid, C., Schleuning, M., Schwerdtfeger, R., Hertenstein, B., Mischak-Weissinger, E., Bunjes, D., Harsdorf, S.V., Scheid, C., Holtick, U., Greinix, H., Keil, F., Schneider, B., Sandherr, M., Bug, G., Tischer, J., Ledderose, G., Hallek, M., Hiddemann, W. & Kolb, H.J. (2006) Long-term survival in refractory acute myeloid leukaemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood, 108, 1092-1099.
74. Siitonen, T., Timonen, T., Juvonen, E., Terava, V., Kutila, A., Honkanen, T., Mikkola, M., Hallman, H., Kauppila, M., Nylanden, P., Poikonen, E., Rauhala, A., Sinisalo, M., Suominen, M., Savolainen, E.R. & Koistinen, P. (2007) Valproic acid combined with 13-cis retinoic acid and 1, 25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. Haematologica, 92, 1119-1122.
75. Smith, A.E., Mohamedali, A.M., Kulasekararaj, A., Lim, Z., Gaken, J., Lea, N.C., Przychodzen, B., Mian, S.A., Nasser, E.E., Shooter, C., Westwood, N.B., Strupp, C., Gattermann, N., Maciejewski, J.P., Germing, U. & Mufti, G.J. (2010) Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low abundance mutant clones with early origins, but indicates no definite prognostic value. Blood, 116, 3923-3932.
76. Soligo, D.A., Oriani, A., Annaloro, C., Cortelezzi, A., Calori, R., Pozzoli, E., Nosella, D., Orazi, A. & Deliliers, G.L. (1994) CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. American Journal of Hematology, 46, 9-17.
77. Sotlar, K., Colak, S., Bache, A., Berezowska, S., Krokowski, M., Bultmann, B., Valent, P. & Horny, H.P. (2010) Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). Journal of Pathology, 220, 586-595.
78. Subira, D., Font, P., Villalon, L., Serrano, C., Askari, E., Gongora, E., Castanon, S., Gonzalo, R., Mata, R., Roman, A. & Llamas, P. (2008) Immunophenotype in chronic myelomonocytic leukaemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders? Translational Research, 151, 240-245.
79. Such, E., Cervera, J., Costa, D., Sole, F., Vallespi, T., Luno, E., Collado, R., Calasanz, M.J., Hernandez-Rivas, J.M., Cigudosa, J.C., Nomdedeu, B., Mallo, M., Carbonell, F., Bueno, J., Ardanaz, M.T., Ramos, F., Tormo, M., Sancho-Tello, R., Del Canizo, C., Gomez, V., Marco, V., Xicoy, B., Bonanad, S., Pedro, C., Bernal, T. & Sanz, G.F. (2011) Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica, 96, 375-83.
80. Symeonidis, A., Van Biezen, A., Mufti, G., Finke, J., Beelen, D., Bornhäuser, M., Greinix, H., Jouet, J., Volin, L., Schwerdtfeger, R., de Witte, T. & Kröger, N. (2010) Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukaemia: the impact of WHO classification and of the conditioning regimen on the transplantation outcome. Annual meeting of the EBMT 2010. Bone Marrow Transplantation, 45, S241, Abstract P803.
81. Tefferi, A. (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukaemia, 24, 1128-1138.
82. Tefferi, A., Lim, K.H., Abdel-Wahab, O., Lasho, T.L., Patel, J., Patnaik, M.M., Hanson, C.A., Pardanani, A., Gilliland, D.G. & Levine, R.L. (2009) Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukaemia, 23, 1343-1345.
83. Venditti, A., Tamburini, A., Buccisano, F., Scimo, M.T., Del Poeta, G., Maurillo, L., Cox, M.C., Abruzzese, E., Tribalto, M., Masi, M. & Amadori, S. (2000) A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes. Annals of Hematology, 79, 138-142.
84. Voglova, J., Chrobak, L., Neuwirtova, R., Malaskova, V. & Straka, L. (2001) Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukaemia - distinct subgroups or two stages of the same disease? Leukemia Research, 25, 493-499.
85. Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., Rabinowitz, J.D., Carroll, M., Su, S.M., Sharp, K.A., Levine, R.L. & Thompson, C.B. (2010) The common feature of leukaemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 17, 225-234.
86. Wattel, E., Guerci, A., Hecquet, B., Economopoulos, T., Copplestone, A., Mahe, B., Couteaux, M.E., Resegotti, L., Voglova, V., Foussard, C., Pegourie, B., Michaux, J.L., Deconinck, E., Stoppa, A.M., Mufti, G., Oscier, D. & Fenaux, P. (1996) A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukaemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood, 88, 2480-2487.
87. Wijermans, P.W., Ruter, B., Baer, M.R., Slack, J.L., Saba, H.I. & Lübbert, M. (2008) Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukaemia (CMML). Leukemia Research, 32, 587-591.
88. Xu, X., Zhao, J., Xu, Z., Peng, B., Huang, Q., Arnold, E. & Ding, J. (2004) Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. Journal of Biological Chemistry, 279, 33946-33957.
89. Xu, Y., McKenna, R.W., Karandikar, N.J., Pildain, A.J. & Kroft, S.H. (2005) Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukaemia from reactive monocytosis. American Journal of Clinical Pathology, 124, 799-806.
90. Zang, D.Y., Deeg, H.J., Gooley, T., Anderson, J.E., Anasetti, C., Sanders, J., Myerson, D., Storb, R. & Appelbaum, F. (2000) Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. British Journal of Haematology, 110, 217-222.